
Reset all filters
01 1Diprosone
02 3Diprospan
03 8Dovobet
Calcipotriol Monohydrate, Betamethasone Dipropionate
Main Therapeutic Indication : Dermatology
Currency : USD
2020 Revenue in Millions : 65
2019 Revenue in Millions : 65
Growth (%) : 1
Calcipotriol Monohydrate, Betamethasone Dipropionate
Main Therapeutic Indication : Dermatology
Currency : USD
2021 Revenue in Millions : 61
2020 Revenue in Millions : 65
Growth (%) : 4
Calcipotriol Monohydrate, Betamethasone Dipropionate
Main Therapeutic Indication : Dermatology
Currency : USD
2021 Revenue in Millions : 87
2020 Revenue in Millions : 83
Growth (%) : 5
Calcipotriol Monohydrate, Betamethasone Dipropionate
Main Therapeutic Indication : Rheumatology
Currency : USD
2021 Revenue in Millions : 125
2020 Revenue in Millions : 118
Growth (%) : 6
Calcipotriol Monohydrate, Betamethasone Dipropionate
Main Therapeutic Indication : Dermatology
Currency : USD
2022 Revenue in Millions : 59
2021 Revenue in Millions : 61
Growth (%) : -3
Calcipotriol Monohydrate, Betamethasone Dipropionate
Main Therapeutic Indication : Rheumatology
Currency : USD
2022 Revenue in Millions : 122
2021 Revenue in Millions : 125
Growth (%) : -2
Calcipotriol Monohydrate, Betamethasone Dipropionate
Main Therapeutic Indication : Dermatology
Currency : USD
2023 Revenue in Millions : 53
2022 Revenue in Millions : 59
Growth (%) : 1
Calcipotriol Monohydrate, Betamethasone Dipropionate
Main Therapeutic Indication : Rheumatology
Currency : USD
2023 Revenue in Millions : 91
2022 Revenue in Millions : 122
Growth (%) : -25
Calcipotriol Monohydrate, Betamethasone Dipropionate
Main Therapeutic Indication : Dermatology
Currency : USD
2024 Revenue in Millions : 52
2023 Revenue in Millions : 53
Growth (%) : -3
Calcipotriol Monohydrate, Betamethasone Dipropionate
Main Therapeutic Indication : Dermatology
Currency : USD
2017 Revenue in Millions : 51
2016 Revenue in Millions : 53
Growth (%) : -4